Technetium Teboroxime

CHEMBL4597794 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Technetium teboroxime is a neutral lipophilic boronate complex that rapidly distributes in myocardium proportional to blood flow, used historically for rapid myocardial perfusion imaging with its fast washout kinetics requiring specialized rapid-acquisition gamma cameras. See technetium-tc-99m-teboroxime for complete pharmacological details. It is now largely replaced by newer myocardial perfusion agents with more favorable imaging characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Technetium teboroxime is a neutral lipophilic boronate complex that rapidly distributes in myocardium proportional to blood flow, used historically for rapid myocardial perfusion imaging with its fast washout kinetics requiring specialized rapid-acquisition gamma cameras. See technetium-tc-99m-teboroxime for complete pharmacological details. It is now largely replaced by newer myocardial perfusion agents with more favorable imaging characteristics.

Yes, Technetium Teboroxime is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4597794. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.